PAPIVAX BIOTECH INCORPORATED
Area: Government, Academia and Research Institutes
Booth No: M534
Website: https://papivax.com/
Exhibitor Profile
PapiVax Biotech leverages the TriGrid™ electroporation platform to develop advanced DNA therapeutics. Our lead vaccine, "PVX4," targets severe cervical lesions (CIN 2/3), replacing surgery with an injection. Phase I achieved 80% complete HPV16 clearance and lesion regression. With US FDA and Taiwan TFDA approvals, multi-center Phase II trials are underway. Moving forward, PapiVax will target pancreatic cancer, bringing Taiwan’s biotech innovation to the global immunotherapy stage.
Brands
Nucleic Acid Immunotherapeutics: From Chronic Viral Infections to Cancer Treatment
Exhibit Products
Exhibitor Press Release
Exhibitors you may be interested in
Highest Rated